Miltefosine to treat leishmaniasis

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 8, 2005, Pages 1381-1388

  Berman, Jonathan ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Clinical trials; Cutaneous leishmaniasis; Miltefosine; Oral therapy; Preclinical evaluation; Visceral leishmaniasis

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; MEGLUMINE ANTIMONATE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PHOSPHATIDYLCHOLINE; PLACEBO; STIBOGLUCONATE SODIUM;

ANOREXIA; ARTHRALGIA; ARTICLE; CHILD HEALTH CARE; CHILL; CLINICAL TRIAL; COLOMBIA; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EYE DISEASE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERAMYLASEMIA; IC 50; INDIA; KIDNEY DYSFUNCTION; LEISHMANIA; LIVER DYSFUNCTION; MYALGIA; NAUSEA; NONHUMAN; OUTPATIENT CARE; PARASITE; PHARMACODYNAMICS; PHOSPHOLIPID SYNTHESIS; POPULATION RESEARCH; RIGOR; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIASIS, CUTANEOUS; LEISHMANIASIS, VISCERAL; PHOSPHORYLCHOLINE;

EID: 22744459815     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.8.1381     Document Type: Article

References (22)

1. ASHFORD RW, DESJEUX P, DERAADT P: Estimation and population at risk of infection and number of cases of leishmaniasis. Parasitology Today (1992) 8:104-105.
2. ALRAJHI AA, IBRAHIM EA, DE VOL EB, KHAIRAT M, FARIS RM, MAGUIRE JH: Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N. Engl. J. Med. (2002) 346:891-895.
3. HERWALDT BL, ARANA BA, NAVIN TR: The natural history of cutaneous leishmaniasis in Guatemala. J. Infect. Dis. (1992) 165:518-527.
4. SOTO J, ARANA BA, TOLEDO J et al.: Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266-1272.
5. SUNDAR S, JHA TK, THAKUR CP et al.: Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2002) 347:1739-1746.
6. JHA TK, OLLIARO P, THAKUR CP et al.: Randomized controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (1998) 316:1200-1205
7. SOTO J, GROGL M, BERMAN J, OLLIARO P: Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:695-698.
8. ACHTERBERG V, GERCKEN G: Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes. Mol. Biochem. Parasitol. (1987) 23:117-122.
9. ACHTERBERG V, GERCKEN G: Metabolism of ether lysophospholipids in Leishmania donovani promastigotes. Mol. Biochem. Parasitol. (1987) 26:277-287.
10. CROFT SL, NEAL RA, PENDERGAST W, CHAN JH: The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. (1987) 36:2633-2636.
11. KUHLENCORD A, MANIERA T, EIBL H, UNGER C: Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. (1992) 36:1630-1634.
12. CROFT SL, SNOWDON D, YARDLEY V: The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. Chemother. (1996) 38:1041-1047.
13. ZUFFEREY R, MAMOUN CB: Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol. Biochem. Parasitol. (2002) 36125:127-134.
14. LIRA R, CONTRERAS LM, RITA RM, URBINA JA: Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J. Antimicrob. Chemother. (2001) 47:537-546.
15. ZENTARIS AG: Impavido registration certificate for Miltefosine capsules 10 mg and 50 mg. Issued by German Registration Authority. November 19 (2004).
16. SUNDAR S, ROSENKAIMER F, MAKHARIA MK et al.: Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 352:1821-1823.
17. JHA TK, SUNDAR S, THAKUR CP et al.: Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. (1999) 341:1795-1800.
18. BHATTACHARYA SK, JHA TK, SUNDAR S et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. (2004) 38:217-221.
19. SINDERMANN H, ENGEL KR, FISCHER C et al.: Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV Infection. Clin. Infect. Dis. (2004) 39:1520-1523.
20. SOTO J, TOLEDO J, GUTIERREZ P et al.: Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. (2001) 33:E57-E61.
21. ZENTARIS AG: Impavido registration certificate for Miltefosine capsules 10 mg and 50 mg. Issued by Drug Controller General India. March 15, 2002.
22. BERMAN J: Development of Miltefosine for the Leishmaniases. Minireviews in Medicinal Chemistry. (2005) (In press).